Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fulcrum Therapeutics (FULC) Return on Sales (2020 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Return on Sales for 6 consecutive years, with 0.43% as the latest value for Q1 2025.

  • On a quarterly basis, Return on Sales rose 1985.0% to 0.43% in Q1 2025 year-over-year; TTM through Mar 2025 was 0.43%, a 1985.0% increase, with the full-year FY2024 number at 0.12%, up 3458.0% from a year prior.
  • Return on Sales was 0.43% for Q1 2025 at Fulcrum Therapeutics, up from 0.54% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.33% in Q3 2024 to a low of 94.71% in Q1 2023.
  • A 5-year average of 14.03% and a median of 7.79% in 2022 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: tumbled -8471bps in 2023, then surged 7444bps in 2024.
  • Fulcrum Therapeutics' Return on Sales stood at 4.64% in 2021, then crashed by -104bps to 9.46% in 2022, then tumbled by -96bps to 18.52% in 2023, then soared by 97bps to 0.54% in 2024, then increased by 21bps to 0.43% in 2025.
  • Per Business Quant, the three most recent readings for FULC's Return on Sales are 0.43% (Q1 2025), 0.54% (Q4 2024), and 0.33% (Q3 2024).